

ModernGraham Valuation

Company Name:

Eli Lilly And Co

Company Ticker LLY

Date of Analysis

3/25/2018



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass all 6 of the following tests.

1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$81,906,882,355	Pass
2. Earnings Stability	Positive EPS for 10 years prior		Fail
3. Dividend Record	Dividend Payments for 10 years prior		Pass
	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end		
4. Earnings Growth		-43.40%	Fail
5. Moderate PEmg Ratio	PEmg < 20	30.37	Fail
6. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	6.73	Fail

Enterprising Investor; must pass all 3 of the following tests, or be suitable for the Defensive Investor.

1. Earnings Stability	Positive EPS for 5 years prior	Fail
2. Dividend Record	Currently Pays Dividend	Pass
3. Earnings Growth	EPSmg greater than 5 years ago	Fail

Suitability

Defensive	No
Enterprising	No

Stage 2: Determination of Intrinsic Value

EPSmg	2.46
MG Growth Estimate	-4.25%
MG Value	\$0.00
MG Value based on 3% Growth	\$35.70
MG Value based on 0% Growth	\$20.93
Market Implied Growth Rate	10.93%

MG Opinion

Current Price	\$74.76
% of Intrinsic Value	N/A
Opinion	Overvalued
MG Grade	D

Stage 3: Information for Further Research

Graham Number	\$33.17
PEmg	30.37
PB Ratio	6.73
Dividend Yield	2.78%
Number of Consecutive Years of Dividend Growth	3

Useful Links:

[ModernGraham tagged articles](#)

[Google Finance](#)

[Yahoo Finance](#)

[GuruFocus](#)


[Morningstar](#)

[MSN Money](#)

[Seeking Alpha](#)

[SEC Filings](#)

EPS History		EPSmg History	
Next Fiscal Year Estimate		Next Fiscal Year Estimate	
Dec2017	\$4.64	Dec2017	\$2.46
Dec2016	-\$0.19	Dec2016	\$1.66
Dec2015	\$2.58	Dec2015	\$2.73
Dec2014	\$2.26	Dec2014	\$2.96
Dec2013	\$2.23	Dec2013	\$3.45
Dec2012	\$4.32	Dec2012	\$4.07
Dec2011	\$3.66	Dec2011	\$3.58
Dec2010	\$3.90	Dec2010	\$3.24
Dec2009	\$4.58	Dec2009	\$2.72
Dec2008	\$3.94	Dec2008	\$1.80
Dec2007	-\$1.89	Dec2007	\$0.93
Dec2006	\$2.71	Dec2006	\$2.30
Dec2005	\$2.45	Dec2005	\$2.11
Dec2004	\$1.81	Dec2004	\$2.02
Dec2003	\$1.66	Dec2003	\$2.21
Dec2002	\$2.37	Dec2002	\$2.50
Dec2001	\$2.50	Dec2001	\$2.52
Dec2000	\$2.55	Balance Sheet Information 12/1/2017	
Dec1999	\$2.79	Long-Term Debt & Capital Lease Obligation	\$9,940,500,000
Dec1998	\$2.46	Total Assets	\$44,981,000,000
	\$1.87	Intangible Assets	\$8,399,300,000
		Total Liabilities	\$33,388,800,000
		Shares Outstanding (Diluted Average)	1,043,692,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other
ModernGraham
posts about the
company

- [47 Companies in the Spotlight This Week – 5/16/15](#)
- [Eli Lilly & Co. Annual Valuation – 2015 \\$LLY](#)
- [58 Companies in the Spotlight This Week – 1/31/15](#)
- [Eli Lilly & Company Quarterly Valuation – January 2015 \\$LLY](#)
- [18 Companies in the Spotlight This Week – 10/25/14](#)

Other
ModernGraham
posts about related
companies

- [Zoetis Inc Valuation – March 2018 \\$ZTS](#)
- [Gilead Sciences Inc Valuation – March 2018 \\$GILD](#)
- [Pfizer Inc Valuation – February 2018 \\$PFE](#)
- [Merck & Co Inc Valuation – February 2018 \\$MRK](#)
- [Johnson & Johnson Valuation – February 2018 \\$JNJ](#)
- [Bristol-Myers Squibb Co Valuation – September 2017 \\$BMY](#)
- [Momenta Pharmaceuticals Inc Valuation – Initial Coverage \\$MNTA](#)
- [Depomed Inc Valuation – Initial Coverage \\$DEPO](#)
- [Endo International PLC Valuation – July 2017 \\$ENDP](#)
- [Biogen Inc Valuation – July 2017 \\$BIIB](#)